IMB Dx, Inc. (KOSDAQ:461030)
South Korea · Delayed Price · Currency is KRW 10,090
+630 (6.66%)
Nov 20, 2025, 3:30 PM KST
IMB Dx Company Description
IMB Dx, Inc. provides liquid biopsy platform in South Korea.
It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test.
The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection.
IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.
IMB Dx, Inc.
| Country | South Korea |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Tae-You Kim |
Contact Details
Address: BYC Highcity Bldg A Seoul, 08506 South Korea | |
| Phone | 82 2 6951 2906 |
| Website | imbdx.com |
Stock Details
| Ticker Symbol | 461030 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7461030009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tae-You Kim | Chief Executive Officer |
| Jin-Won Joo | Chief Financial Officer |